Navigation Links
Nuvilex, Inc. Announces Monthly Investor Conference Call
Date:5/19/2009

CHERRY HILL, N.J., May 19 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products, today announced that its monthly investor conference call will be held on Tuesday, June 2, 2009 at 4:30 PM Eastern Time.

To participate in the call, please dial 1-877-407-4018 (U.S.) and 1-201-689-8471 (international). The call will also be webcast. To access the webcast, please go to:

http://viavid.net/dce.aspx?sid=000064BD

The conference call will be taped and available for replay from June 2, 2009 at 7:30 PM ET to June 9, 2009 at 11:59 PM ET. The replay number is 1-877-660-6853 (U.S.) and 1-201-612-7415 (international). To listen to the replay, please provide the account code 3055 and conference ID number 323514. A replay of the webcast will be available for one month. To access the webcast replay, please visit www.nuvilex.com.

About Nuvilex, Inc.

Nuvilex is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:

    Blair Barnes
    SVP and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email:  bbarnes@nuvilex.com

    Amy Glynn/Ashleigh Barreto
    The Ruth Group
    Ph: 646-536-7023/7028
    Email: aglynn@theruthgroup.com
    Email: abarreto@theruthgroup.com

    Press Contact:
    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email:  pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
2. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
3. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
4. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
5. Nuvilex, Inc. Announces Investor Conference Call and Open House
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... World Patent Marketing , a ... invention which aids in proper muscle development. , "The Gym & Exercise Equipment ... of World Patent Marketing. "Globalization has threatened the future growth of the industry ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program (GFCP), ... announce the launch of the GFCP Scoop in response to consumer ... of the GFCP Scoop site is to keep the gluten-free community ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of ... to blame for the majority of skin cancer deaths. More than 10,000 people are expected ... age at diagnosis is 62, it is the one of the most commonly diagnosed cancers ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is ... field as more patients are discovering the many different ways they can change and ... available to them and which ones might work for their smiles. , “One ...
(Date:4/29/2016)... ... , ... New York City based oral and maxillofacial surgeon Dr. Majid Jamali is ... treat obstructive sleep apnea. Dr. Jamali is proud to offer this permanent solution to patients ... or both jaw bones. This surgery is performed to correct the alignment of the jaw. ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 Acquisition Expands ... Product Development Capabilities in North America ... . Indegene ( http://www.indegene.com ), ... acquisition of Skura Corporation,s life science business. Skura,s ... sales enablement technology for life science organizations and ...
(Date:4/29/2016)... 29, 2016 ... Sanofi, leader mondial et ... résultats pour le premier trimestre 2016. ... Contamine, commente les résultats du premier ... pour le reste de l,année. ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology company built ... Dr. Alfredo Zurlo as Chief Medical Officer. ... years clinical experience and a proven track record in ... at Mologen AG where he was Chief Medical Officer ... held various positions at F Hoffmann La Roche and ...
Breaking Medicine Technology: